S&P 500   3,297.89 (+0.82%)
DOW   26,669.51 (+0.91%)
QQQ   269.63 (+1.44%)
AAPL   437.09 (+2.84%)
MSFT   214.41 (+4.59%)
FB   254.50 (+0.33%)
GOOGL   1,476.22 (-0.79%)
AMZN   3,126.54 (-1.21%)
NVDA   443.32 (+4.41%)
CGC   18.25 (-0.16%)
BABA   257.11 (+2.43%)
TSLA   1,497.86 (+4.69%)
MU   50.40 (+0.68%)
GE   6.15 (+1.32%)
AMD   77.89 (+0.59%)
T   29.53 (-0.17%)
F   6.68 (+1.06%)
ACB   10.07 (-1.18%)
GILD   71.81 (+3.28%)
NFLX   502.09 (+2.70%)
DIS   116.24 (-0.60%)
BAC   25.01 (+0.52%)
BA   161.19 (+2.02%)
S&P 500   3,297.89 (+0.82%)
DOW   26,669.51 (+0.91%)
QQQ   269.63 (+1.44%)
AAPL   437.09 (+2.84%)
MSFT   214.41 (+4.59%)
FB   254.50 (+0.33%)
GOOGL   1,476.22 (-0.79%)
AMZN   3,126.54 (-1.21%)
NVDA   443.32 (+4.41%)
CGC   18.25 (-0.16%)
BABA   257.11 (+2.43%)
TSLA   1,497.86 (+4.69%)
MU   50.40 (+0.68%)
GE   6.15 (+1.32%)
AMD   77.89 (+0.59%)
T   29.53 (-0.17%)
F   6.68 (+1.06%)
ACB   10.07 (-1.18%)
GILD   71.81 (+3.28%)
NFLX   502.09 (+2.70%)
DIS   116.24 (-0.60%)
BAC   25.01 (+0.52%)
BA   161.19 (+2.02%)
S&P 500   3,297.89 (+0.82%)
DOW   26,669.51 (+0.91%)
QQQ   269.63 (+1.44%)
AAPL   437.09 (+2.84%)
MSFT   214.41 (+4.59%)
FB   254.50 (+0.33%)
GOOGL   1,476.22 (-0.79%)
AMZN   3,126.54 (-1.21%)
NVDA   443.32 (+4.41%)
CGC   18.25 (-0.16%)
BABA   257.11 (+2.43%)
TSLA   1,497.86 (+4.69%)
MU   50.40 (+0.68%)
GE   6.15 (+1.32%)
AMD   77.89 (+0.59%)
T   29.53 (-0.17%)
F   6.68 (+1.06%)
ACB   10.07 (-1.18%)
GILD   71.81 (+3.28%)
NFLX   502.09 (+2.70%)
DIS   116.24 (-0.60%)
BAC   25.01 (+0.52%)
BA   161.19 (+2.02%)
S&P 500   3,297.89 (+0.82%)
DOW   26,669.51 (+0.91%)
QQQ   269.63 (+1.44%)
AAPL   437.09 (+2.84%)
MSFT   214.41 (+4.59%)
FB   254.50 (+0.33%)
GOOGL   1,476.22 (-0.79%)
AMZN   3,126.54 (-1.21%)
NVDA   443.32 (+4.41%)
CGC   18.25 (-0.16%)
BABA   257.11 (+2.43%)
TSLA   1,497.86 (+4.69%)
MU   50.40 (+0.68%)
GE   6.15 (+1.32%)
AMD   77.89 (+0.59%)
T   29.53 (-0.17%)
F   6.68 (+1.06%)
ACB   10.07 (-1.18%)
GILD   71.81 (+3.28%)
NFLX   502.09 (+2.70%)
DIS   116.24 (-0.60%)
BAC   25.01 (+0.52%)
BA   161.19 (+2.02%)
Log in

NYSE:ABTAbbott Laboratories Stock Price, Forecast & News

$100.56
-0.08 (-0.08 %)
(As of 08/3/2020 01:28 PM ET)
Add
Compare
Today's Range
$100.22
Now: $100.56
$101.54
50-Day Range
$87.30
MA: $93.64
$102.52
52-Week Range
$61.61
Now: $100.56
$102.89
Volume104,210 shs
Average Volume4.87 million shs
Market Capitalization$177.87 billion
P/E Ratio58.13
Dividend Yield1.43%
Beta0.99
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company's Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.
Read More
Abbott Laboratories logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.3Community Rank: 2.7Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.98 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryHealth Care Equipment
SectorMedical
CUSIP00282410
CIK1800
Phone224-667-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.90 billion
Cash Flow$4.99 per share
Book Value$17.70 per share

Profitability

Net Income$3.69 billion

Miscellaneous

Employees107,000
Outstanding Shares1,768,840,000
Market Cap$177.87 billion
Next Earnings Date10/21/2020 (Estimated)
OptionableOptionable
$100.56
-0.08 (-0.08 %)
(As of 08/3/2020 01:28 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABT News and Ratings via Email

Sign-up to receive the latest news and ratings for ABT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Abbott Laboratories (NYSE:ABT) Frequently Asked Questions

How has Abbott Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Abbott Laboratories' stock was trading at $78.09 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABT shares have increased by 28.8% and is now trading at $100.56.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Abbott Laboratories?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last year. There are currently 2 sell ratings, 4 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Abbott Laboratories
.

When is Abbott Laboratories' next earnings date?

Abbott Laboratories is scheduled to release its next quarterly earnings announcement on Wednesday, October 21st 2020.
View our earnings forecast for Abbott Laboratories
.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) posted its quarterly earnings results on Thursday, July, 16th. The healthcare product maker reported $0.57 EPS for the quarter, beating the consensus estimate of $0.42 by $0.15. The healthcare product maker had revenue of $7.33 billion for the quarter, compared to analyst estimates of $6.85 billion. Abbott Laboratories had a return on equity of 17.34% and a net margin of 9.89%. The company's quarterly revenue was down 8.2% compared to the same quarter last year. During the same quarter last year, the business earned $0.82 earnings per share.
View Abbott Laboratories' earnings history
.

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, June 12th. Stockholders of record on Wednesday, July 15th will be given a dividend of $0.36 per share on Monday, August 17th. This represents a $1.44 annualized dividend and a dividend yield of 1.43%. The ex-dividend date of this dividend is Tuesday, July 14th. This is a positive change from Abbott Laboratories's previous quarterly dividend of $0.08.
View Abbott Laboratories' dividend history
.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories issued an update on its FY20 earnings guidance on Thursday, July, 16th. The company provided earnings per share guidance of at least $3.25 for the period, compared to the Thomson Reuters consensus estimate of $2.86.

What price target have analysts set for ABT?

17 brokerages have issued 12 month price objectives for Abbott Laboratories' stock. Their forecasts range from $84.00 to $125.00. On average, they anticipate Abbott Laboratories' share price to reach $105.64 in the next twelve months. This suggests a possible upside of 5.1% from the stock's current price.
View analysts' price targets for Abbott Laboratories
.

Has Abbott Laboratories been receiving favorable news coverage?

Headlines about ABT stock have trended negative recently, InfoTrie reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Abbott Laboratories earned a media sentiment score of -2.9 on InfoTrie's scale. They also gave news headlines about the healthcare product maker a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Abbott Laboratories
.

Are investors shorting Abbott Laboratories?

Abbott Laboratories saw a drop in short interest in July. As of July 15th, there was short interest totaling 10,170,000 shares, a drop of 6.7% from the June 30th total of 10,900,000 shares. Based on an average trading volume of 6,450,000 shares, the short-interest ratio is currently 1.6 days. Currently, 0.6% of the company's shares are sold short.
View Abbott Laboratories' Current Options Chain
.

Who are some of Abbott Laboratories' key competitors?

What other stocks do shareholders of Abbott Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Abbott Laboratories investors own include AbbVie (ABBV), Johnson & Johnson (JNJ), AT&T (T), Walt Disney (DIS), NVIDIA (NVDA), Cisco Systems (CSCO), Pfizer (PFE), Home Depot (HD), Intel (INTC) and Verizon Communications (VZ).

Who are Abbott Laboratories' key executives?

Abbott Laboratories' management team includes the following people:
  • Mr. Miles D. White M.B.A., Chairman & CEO (Age 64)
  • Mr. Robert B. Ford, Pres & COO (Age 45)
  • Mr. Brian B. Yoor, Exec. VP of Fin. & CFO (Age 49)
  • Mr. Hubert L. Allen, Exec. VP, Gen. Counsel & Sec. (Age 53)
  • Mr. Stephen R. Fussell, Exec. VP of HR (Age 62)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

Who are Abbott Laboratories' major shareholders?

Abbott Laboratories' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.40%), New York State Teachers Retirement System (0.14%), Raymond James & Associates (0.12%), WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST (0.11%), Loring Wolcott & Coolidge Fiduciary Advisors LLP MA (0.10%) and Envestnet Asset Management Inc. (0.10%). Company insiders that own Abbott Laboratories stock include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Brian J Blaser, Christopher J Scoggins, Daniel Gesua Sive Salvadori, Hubert L Allen, Jaime Contreras, Jared Watkin, John F Ginascol, John G Stratton, John M Capek, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Miles D White, Philip P Boudreau, Randel William Woodgrift, Roger Bird, Roxanne S Austin, Sally E Blount, Sharon J Bracken and Stephen R Fussell.
View institutional ownership trends for Abbott Laboratories
.

Which institutional investors are selling Abbott Laboratories stock?

ABT stock was sold by a variety of institutional investors in the last quarter, including Coho Partners Ltd., NN Investment Partners Holdings N.V., Hexavest Inc., Candriam Luxembourg S.C.A., Prudential PLC, Montag & Caldwell LLC, Sumitomo Mitsui Trust Holdings Inc., and Zurcher Kantonalbank Zurich Cantonalbank. Company insiders that have sold Abbott Laboratories company stock in the last year include Andrea F Wainer, Andrew H Lane, Brian B Yoor, Christopher J Scoggins, Jared Watkin, John F Ginascol, Joseph J Manning, Lisa D Earnhardt, Mary K Moreland, Michael D Dale, Michael J Pederson, Philip P Boudreau, Randel William Woodgrift, and Roxanne S Austin.
View insider buying and selling activity for Abbott Laboratories
.

Which institutional investors are buying Abbott Laboratories stock?

ABT stock was acquired by a variety of institutional investors in the last quarter, including WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST, Mn Services Vermogensbeheer B.V., Assenagon Asset Management S.A., Envestnet Asset Management Inc., First Trust Advisors LP, PGGM Investments, Pacer Advisors Inc., and SG Americas Securities LLC. Company insiders that have bought Abbott Laboratories stock in the last two years include John G Stratton, and Randel William Woodgrift.
View insider buying and selling activity for Abbott Laboratories
.

How do I buy shares of Abbott Laboratories?

Shares of ABT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Abbott Laboratories' stock price today?

One share of ABT stock can currently be purchased for approximately $100.56.

How big of a company is Abbott Laboratories?

Abbott Laboratories has a market capitalization of $177.87 billion and generates $31.90 billion in revenue each year. The healthcare product maker earns $3.69 billion in net income (profit) each year or $3.24 on an earnings per share basis. Abbott Laboratories employs 107,000 workers across the globe.

What is Abbott Laboratories' official website?

The official website for Abbott Laboratories is www.abbott.com.

How can I contact Abbott Laboratories?

Abbott Laboratories' mailing address is 100 ABBOTT PARK ROAD D-322 AP6D, ABBOTT PARK IL, 60064. The healthcare product maker can be reached via phone at 224-667-6100.

This page was last updated on 8/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.